Pier Capital, LLC Alector, Inc. Transaction History

Pier Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$5.86 - $7.93 $27,219 - $36,834	-4,645 Reduced 1.28%	358,963 $2.16 Million
Q1 2023 May 10, 2023	SELL	$5.85 - $9.84 $45,284 - $76,171	-7,741 Reduced 2.08%	363,608 $2.25 Million
Q4 2022 Feb 15, 2023	BUY	$6.88 - $9.55 $1,121 - $1,556	163 Added 0.04%	371,349 $3.43 Million
Q3 2022 Nov 15, 2022	BUY	$8.19 - $13.2 $782,611 - $1.26 Million	95,557 Added 34.67%	371,186 $3.51 Million
Q2 2022 Aug 15, 2022	SELL	$7.65 - $14.24 $22,865 - $42,563	-2,989 Reduced 1.07%	275,629 $2.8 Million

Q1 2022 May 10, 2022	SELL	$13.02 - $20.78 $355,485 - $567,356	-27,303 Reduced 8.92%	278,618 $3.97 Million
Q4 2021 Feb 10, 2022	SELL	$19.35 - $25.54 $11,900 - $15,707	-615 Reduced 0.2%	305,921 $6.32 Million
Q3 2021 Nov 10, 2021	SELL	$21.65 - $39.49 $657,683 - $1.2 Million	-30,378 Reduced 9.02%	306,536 $7 Million
Q2 2021 Aug 12, 2021	SELL	$15.5 - $22.48 $2.61 Million - $3.79 Million	-168,489 Reduced 33.34%	336,914 $7.02 Million
Q1 2021 May 13, 2021	BUY	$14.84 - $22.23 $7.5 Million - $11.2 Million	505,403 New	505,403 $10.2 Million

161

59.8M

67.8K

200

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $364M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pier Capital, LLC with notifications on news.